By calibrating hepcidin through SOCS3-, FGL1-, and HIF2α-mediated control of IL-6-STAT3 and BMP-SMAD, RYGB mitigates the risk of profound iron deficiency while preserving beneficial macrophage and metabolic adaptations. Here, IL6 is linked to Iron deficiency anemia.